Clinical Trials
139 trialsFORAGER-2
Eli Lilly and Company
TroFuse-031
Merck Sharp & Dohme LLC
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
National Cancer Institute (NCI)
ENVISION
UroGen Pharma Ltd.
EV-309
Astellas Pharma Inc
SunRISe-2
Janssen Research & Development, LLC
SunRISe-3
Janssen Research & Development, LLC
Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery
SWOG Cancer Research Network
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NRG Oncology
MK-3475-992
Merck Sharp & Dohme LLC
BCG for Therapeutic Use Phase â…¢ Clinical Trial
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
AstraZeneca
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Seagen Inc.
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Bristol-Myers Squibb
VOLGA
AstraZeneca
GAIN-BCG
Alliance for Clinical Trials in Oncology
EVER
Verity Pharmaceuticals Inc.
ADVANCED-3
Protara Therapeutics
BOOST
Relmada Therapeutics, Inc.
NIAGARA
AstraZeneca
RESCUE
Relmada Therapeutics, Inc.
KEYNOTE-B15
Merck Sharp & Dohme LLC
NILE
AstraZeneca
A Study of Surgical Techniques During Cystectomy
Memorial Sloan Kettering Cancer Center
CREST
Pfizer
UTOPIA
UroGen Pharma Ltd.
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
CG Oncology, Inc.
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Astellas Pharma Inc
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
INCyst
Centre Hospitalier Universitaire Vaudois
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
Johns Hopkins University
VESPER
University Hospital, Rouen
CheckMate 7G8
Bristol-Myers Squibb
FIDURA
Sahlgrenska University Hospital
KEYNOTE-866
Merck Sharp & Dohme LLC
KEYNOTE-905
Merck Sharp & Dohme LLC
Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)
Ferring Pharmaceuticals
TEMPO-MIBC
University of Rome Tor Vergata
NAUTICAL
University Health Network, Toronto
Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBt
Regina Elena Cancer Institute
IMvigor130
Hoffmann-La Roche
A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
BART
Tata Memorial Centre
ALBAN
UNICANCER
IMMUNOBCG
University of Campinas, Brazil
Adjuvant Intraarterial Chemotherapy Following Surgery to Treat Locally Advanced Bladder Cancer
Sun Yat-sen University
Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer
Photocure
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.